Premium
Methyl‐p‐Hydroxyphenyllactate‐esterase activity and type‐II estrogen‐binding sites in ovarian cancer: Correlation with biological and clinico‐pathological parameters
Author(s) -
Ranelletti Franco O.,
Scambia Giovanni,
Panici Pierluigi Benedetti,
Piantelu Mauro,
Ferrandina Gabriella,
D'agostino Giuseppe,
De Vincenzo Rosa,
Rinelli Alessandro,
Isola Giulio,
Mancuso Salvatore
Publication year - 1995
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910620508
Subject(s) - ovarian cancer , estrogen , medicine , endocrinology , pathological , cancer , biology
Abstract We examined the levels of activity of methyl‐p‐hydroxyphenyl‐lactate esterase (MeHPLA‐ase) and cytosolic Type‐II‐estrogen‐binding sites (Type‐II EBS) in 61 and 71 cases, respectively, of primary ovarian cancer. MeHPLA‐ase activity and Type‐II EBS were seen to by asymmetrically distributed, in that levels were skewed towards the lower values. A statistically significant direct correlation was found between MeHPLA‐ase activity and Type‐II EBS. MeHPLA‐ase activity and Type‐II EBS were inversely correlated with ER and PR levels and showed a trend towards inverse correlation with the percentage of cells in S‐phase of the cell cycle. MeHPLA‐ase activity and Type‐II EBS did not correlate with clinico‐pathological parameters. The median MeHPLA‐ase activity tended to be higher in responders than in unresponsive patients, but statistical significance was not reached. Higher Type‐II‐EBS levels were found in cases showing complete and partial response to chemotherapy than in cases which did not respond. A statistically significant relationship was found between high MeHPLA‐ase activity and longer overall survival. © 1995 Wiley‐Liss, Inc.